Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2023 | Aug. 14, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2023 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q2 | |
Trading Symbol | IMPL | |
Entity Registrant Name | IMPEL PHARMACEUTICALS INC. | |
Entity Central Index Key | 0001445499 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Current Reporting Status | Yes | |
Entity Shell Company | false | |
Entity File Number | 001-40353 | |
Entity Tax Identification Number | 26-3058238 | |
Entity Address, Address Line One | 201 Elliott Avenue West | |
Entity Address, Address Line Two | Suite 260 | |
Entity Address, City or Town | Seattle | |
Entity Address, State or Province | WA | |
Entity Address, Postal Zip Code | 98119 | |
City Area Code | 206 | |
Local Phone Number | 568-1466 | |
Entity Common Stock, Shares Outstanding | 23,749,005 | |
Entity Interactive Data Current | Yes | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Security Exchange Name | NASDAQ | |
Entity Incorporation, State or Country Code | DE | |
Document Quarterly Report | true | |
Document Transition Report | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheet (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 15,162 | $ 60,654 |
Trade receivables, net | 6,801 | 7,444 |
Inventory | 6,985 | 8,427 |
Prepaid expenses and other current assets | 3,956 | 3,284 |
Total current assets | 32,904 | 79,809 |
Property and equipment, net | 3,944 | 3,863 |
Operating lease right-of-use assets | 4,442 | 3,132 |
Other assets | 3,517 | 1,746 |
Total assets | 44,807 | 88,550 |
Current liabilities: | ||
Accounts payable | 3,458 | 6,092 |
Accrued and other liabilities | 11,818 | 12,503 |
Current portion of long-term debt | 47,823 | 0 |
Current portion of deferred royalty obligation | 56,394 | 2,027 |
Current portion of operating lease liability | 1,728 | 1,541 |
Total current liabilities | 121,221 | 22,163 |
Operating lease liability, net of current portion | 2,744 | 1,573 |
Deferred royalty obligation, net of current portion | 0 | 60,899 |
Long-term debt | 0 | 48,072 |
Total liabilities | 123,965 | 132,707 |
Commitments and contingencies (Note 6) | ||
Stockholders '(deficit) equity | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized: none issued | 0 | 0 |
Common stock, $0.001 par value; 300,000,000 shares authorized; 23,749,005 and 23,739,313 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 24 | 24 |
Additional paid-in capital | 279,352 | 276,929 |
Accumulated deficit | (358,534) | (321,110) |
Total stockholders (deficit) equity | (79,158) | (44,157) |
Total liabilities and stockholders (deficit) equity | $ 44,807 | $ 88,550 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheet (Parenthetical) (Unaudited) - $ / shares | Jun. 30, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares Issued | 0 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 300,000,000 | 300,000,000 |
Common stock, shares issued | 23,749,005 | 23,739,313 |
Common stock, shares outstanding | 23,749,005 | 23,739,313 |
Condensed Consolidated Statemen
Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Income Statement [Abstract] | ||||
Product revenue, net | $ 6,584 | $ 2,803 | $ 10,956 | $ 4,562 |
Cost of goods sold | 3,220 | 1,737 | 5,505 | 2,770 |
Gross profit | 3,364 | 1,066 | 5,451 | 1,792 |
Operating expenses: | ||||
Research and development | 200 | 3,951 | 3,203 | 7,601 |
Selling, general and administrative | 19,268 | 18,095 | 41,307 | 37,894 |
Restructuring | 0 | 1,481 | ||
Total operating expenses | 19,468 | 22,046 | 45,991 | 45,495 |
Loss from operations | (16,104) | (20,980) | (40,540) | (43,703) |
Other income (expense), net : | ||||
Interest income (expense), net | (3,015) | (3,450) | (5,948) | (7,877) |
Other income (expense), net | 11,762 | (774) | 9,064 | (594) |
Total other income (expense), net | 8,747 | (4,224) | 3,116 | (8,471) |
Loss before income taxes | (7,357) | (25,204) | (37,424) | (52,174) |
Provision (benefit) for income taxes | 0 | 0 | 0 | 0 |
Net loss and comprehensive loss | $ (7,357) | $ (25,204) | $ (37,424) | $ (52,174) |
Net loss per share - basic | $ (0.31) | $ (1.09) | $ (1.58) | $ (2.25) |
Net loss per share - diluted | $ (0.31) | $ (1.09) | $ (1.58) | $ (2.25) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | 23,748,008 | 23,178,302 | 23,746,946 | 23,161,133 |
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted | 23,748,008 | 23,178,302 | 23,746,946 | 23,161,133 |
Condensed Consolidated Statem_2
Condensed Consolidated Statement of Changes in Redeemable Convertible Preferred Stock and Stockholders Deficit (Unaudited) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-In Capital | Accumulated Deficit |
Beginning Balance at Dec. 31, 2021 | $ 52,508 | $ 23 | $ 267,283 | $ (214,798) |
Beginning Balance, Shares at Dec. 31, 2021 | 23,123,062 | |||
Stock-based compensation expense | 1,795 | 1,795 | ||
Issuance of common stock upon the exercise of stock options | 149 | 149 | ||
Issuance of common stock upon the exercise of stock options, Shares | 50,235 | |||
Net loss and comprehensive loss | (26,970) | (26,970) | ||
Ending Balance at Mar. 31, 2022 | 27,482 | $ 23 | 269,227 | (241,768) |
Ending Balance, Shares at Mar. 31, 2022 | 23,173,297 | |||
Beginning Balance at Dec. 31, 2021 | 52,508 | $ 23 | 267,283 | (214,798) |
Beginning Balance, Shares at Dec. 31, 2021 | 23,123,062 | |||
Net loss and comprehensive loss | (52,174) | |||
Ending Balance at Jun. 30, 2022 | 3,910 | $ 23 | 270,859 | (266,972) |
Ending Balance, Shares at Jun. 30, 2022 | 23,196,313 | |||
Beginning Balance at Mar. 31, 2022 | 27,482 | $ 23 | 269,227 | (241,768) |
Beginning Balance, Shares at Mar. 31, 2022 | 23,173,297 | |||
Stock-based compensation expense | 1,579 | 1,579 | ||
Issuance of common stock upon the exercise of stock options | 53 | 53 | ||
Issuance of common stock upon the exercise of stock options, Shares | 23,016 | |||
Net loss and comprehensive loss | (25,204) | (25,204) | ||
Ending Balance at Jun. 30, 2022 | 3,910 | $ 23 | 270,859 | (266,972) |
Ending Balance, Shares at Jun. 30, 2022 | 23,196,313 | |||
Beginning Balance at Dec. 31, 2022 | (44,157) | $ 24 | 276,929 | (321,110) |
Beginning Balance, Shares at Dec. 31, 2022 | 23,739,313 | |||
Release Of Restricted Stock Units Shares | 6,944 | |||
Stock-based compensation expense | 1,319 | 1,319 | ||
Net loss and comprehensive loss | (30,067) | (30,067) | ||
Ending Balance at Mar. 31, 2023 | (72,905) | $ 24 | 278,248 | (351,177) |
Ending Balance, Shares at Mar. 31, 2023 | 23,746,257 | |||
Beginning Balance at Dec. 31, 2022 | $ (44,157) | $ 24 | 276,929 | (321,110) |
Beginning Balance, Shares at Dec. 31, 2022 | 23,739,313 | |||
Issuance of common stock upon the exercise of stock options, Shares | 2,748 | |||
Net loss and comprehensive loss | $ (37,424) | |||
Ending Balance at Jun. 30, 2023 | (79,158) | $ 24 | 279,352 | (358,534) |
Ending Balance, Shares at Jun. 30, 2023 | 23,749,005 | |||
Beginning Balance at Mar. 31, 2023 | (72,905) | $ 24 | 278,248 | (351,177) |
Beginning Balance, Shares at Mar. 31, 2023 | 23,746,257 | |||
Stock-based compensation expense | 1,099 | 1,099 | ||
Issuance of common stock upon the exercise of stock options | 5 | 5 | ||
Issuance of common stock upon the exercise of stock options, Shares | 2,748 | |||
Net loss and comprehensive loss | (7,357) | (7,357) | ||
Ending Balance at Jun. 30, 2023 | $ (79,158) | $ 24 | $ 279,352 | $ (358,534) |
Ending Balance, Shares at Jun. 30, 2023 | 23,749,005 |
Condensed Consolidated Statem_3
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Cash flows from operating activities: | ||
Net loss | $ (37,424) | $ (52,174) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation | 2,418 | 3,374 |
Depreciation and amortization | 215 | 599 |
Non-cash lease expense | 813 | 537 |
Non-cash interest expense and amortization of debt discount and issuance costs | 2,120 | 2,696 |
Loss on early extinguishment of debt | 0 | 3,251 |
Change in fair value of derivatives | (8,900) | 558 |
Change in fair value of warrant liabilities | (193) | 74 |
Write-down of inventory to net realizable value | 1,070 | 0 |
Long-lived asset impairment | 417 | 0 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 643 | (3,442) |
Inventory | (1,256) | (2,622) |
Prepaid expenses and other current assets | (673) | (2,295) |
Other assets | (20) | 0 |
Accounts payable | (2,634) | (1,620) |
Accrued liabilities | (414) | (1,394) |
Operating Lease | (765) | (520) |
Net cash used in operating activities | (44,583) | (52,978) |
Cash flows from investing activities: | ||
Purchases of property and equipment | (914) | (215) |
Net cash used in investing activities | (914) | (215) |
Cash flows from financing activities: | ||
Proceeds from deferred royalty obligation, net of issuance costs | 0 | 48,418 |
Proceeds from issuance of long-term debt, net of issuance costs | 0 | 47,440 |
Payments on long-term debt, including final payment | 0 | (32,853) |
Proceeds from issuance of common stock upon exercise of stock options | 5 | 198 |
Payment of deferred offering costs | 0 | (395) |
Net cash provided by financing activities | 5 | 62,808 |
Net (decrease) increase in cash and cash equivalents | (45,492) | 9,615 |
Cash — Beginning of period | 60,654 | 88,212 |
Cash — End of period | 15,162 | 97,827 |
Supplemental disclosures of cash flow information: | ||
Right-of-use asset obtained in exchange for new operating lease liability | 2,123 | 3,583 |
Accrued inventory purchases | 122 | 1,483 |
Recognition of derivative liabilities | 0 | 1,905 |
Purchase of property and equipment included in accounts payable and accrued liabilities | $ 104 | $ 4 |
Organization and Description of
Organization and Description of Business | 6 Months Ended |
Jun. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Description of Business | 1. Organization and Description of Business Impel Pharmaceuticals Inc. (“the Company”, "we", and "our"), is a commercial-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. The Company's lead product, Trudhesa (dihydroergotamine mesylate) Nasal Spray was approved by the U.S. Food and Drug Administration ("FDA") in September of 2021. Using the Company’s proprietary Precision Olfactory Delivery (POD®) technology, Trudhesa gently delivers dihydroergotamine mesylate (DHE), a proven, well-established therapeutic, quickly to the bloodstream through the vascular-rich upper nasal space. The Company’s strategy is to pair its POD®, upper nasal delivery technology with well-understood therapeutics or other therapeutics where rapid vascular absorption is preferred to drive therapeutic benefit, improve patient outcomes, reduce drug development risk and expand the commercial opportunity within its target diseases. The Company was incorporated under the laws of the State of Delaware on July 24, 2008, and maintains its headquarters and principal operations in Seattle, Washington. In April of 2022, the Company changed its name from Impel NeuroPharma, Inc. to Impel Pharmaceuticals Inc. Recent Developments From the Company’s inception through June 30, 2023, it raised an aggregate of $ 397.8 million in proceeds from the issuance of its common stock, proceeds pursuant to the Revenue Interest Financing Agreement (deferred royalty obligation), sale and issuance of redeemable convertible preferred stock, convertible notes, debt and warrants. The Company had a cash and cash equivalents balance of $ 15.2 million as of June 30, 2023. The Company currently has an effective 2022 Shelf Registration Statement on file with the Securities and Exchange Commission ("SEC"). The 2022 Shelf Registration Statement permits the offering, issuance and sale by the Company of up to an aggregate offering price of $ 200.0 million of common stock, preferred stock, debt securities, warrants, subscription rights and/or units in one or more offerings and in any combination. Further, the Senior Credit Agreement with Oaktree Fund Administration, LLC as administrative agent, and the lenders party thereto, or collectively Oaktree, as further described in Note 8, requires maintaining a minimum of $ 12.5 million in unrestricted cash and cash equivalents on hand to avoid an event of default under the Senior Credit Agreement. Among other loan covenant requirements, the Senior Credit Agreement also requires the Company to provide an audit opinion of its annual financial statements not subject to any "going concern" or like qualification or exception or explanatory paragraph of going concern footnote, however, any such audit report shall not be considered qualified due to the inclusion of an explanatory paragraph in the audit opinion based on the impending maturity date of any indebtedness within twelve months from the date of issuance of the annual financial statements, the prospective breach of any financial covenant thereunder or liquidity issues due to ordinary course liabilities. On March 22, 2023, the Company entered into the Oaktree Letter Agreement in connection with its Senior Credit Agreement, to obtain a waiver from Oaktree of any default or event of default arising from the going concern explanatory paragraph included in the report of its Independent Registered Public Accounting Firm on its audited consolidated financial statements for the year ended December 31, 2022. As of the filing date of this Form 10-Q, the Company was not in compliance with maintaining the minimum liquidity covenant of $ 12.5 million in unrestricted cash and cash equivalents. Although the Company is currently in default, Oaktree has not taken any action to accelerate the maturity of the debt under the Senior Credit Agreement. The Company does not currently have sufficient liquidity to fund payment of the amounts that would be due under the Senior Credit Agreement nor does management have projected future cash flows to repay these outstanding borrowings under the Senior Credit Agreement. The Company’s inability to raise additional c apital on acceptable terms in the near future, whether for purposes of funding payments required under the Senior Credit Agreement or providing additional liquidity needed for its operations, could have a material adverse effect on its business, results of operations, liquidity and financial condition. In response to these conditions, the Company is currently in negotiations with Oaktree to seek a forbearance and amendment agreement to remedy the Company’s current and anticipated noncompliance with its covenants under the Senior Credit Agreement. The Company is also currently in negotiations with Oaktree and other investors regarding the terms of an approximately $ 20.0 million potential bridge financing facility. The Comp any continues to evaluate potential financing, business development and other strategic alternatives, that might be available to us to maximize stockholder value, particularly given the Company’s current liquidity position. Potential strategic alternatives may include restructuring or refinancing of the Company’s debt, seeking additional debt or equity capital, reducing or delaying the Company’s business activities, a sale of all or a portion of the Company, a combination of these, or other strategic transactions. We currently have no commitments to engage in any specific strategic transaction and there can be no assurance that we will be able to complete additional or alternative financings, business development transactions or other strategic alternatives. Further, there can be no assurances that they will result in the completion of any such amendment, transaction or other alternative that would alleviate such conditions under the Senior Credit Agreement or the circumstances that give rise to substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the filing date of this Form 10-Q. If the strategic process is unsuccessful, our Board may decide to obtain relief under the US Bankruptcy Code. The Company has hired advisors, if needed, to assist with filing for bankruptcy protection. Accordingly, the Company determined that it cannot be certain that the Company’s plans and initiatives would be effectively implemented within one year after the filing date. Without giving effect to the Company’s plans and initiatives, it is unlikely that the Company will be able to generate sufficient cash flows to meet its required financial obligations, including its debt service and other obligations due to third parties within one year after filing date of this Form 10-Q. The existence of these conditions and events raise substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the issuance of these interim financial statements. All outstanding borrowings under the Senior Credit Agreement and deferred royalty obligation are classified as short term on the Condensed Consolidated Balance Sheets as of June 30, 2023 due to the debt covenant violation at the time of the issuance of these interim financial statements. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and rules and regulations of the SEC for interim financial reporting. The condensed consolidated financial statements include the operations of Impel Pharmaceuticals Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation. The condensed consolidated balance sheet as of June 30, 2023, the condensed consolidated statements of operations and comprehensive loss, and changes in stockholders’ (deficit) equity for the three and six months ended June 30, 2023 and 2022 and cash flows for the six months ended June 30, 2023 and 2022 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position as of June 30, 2023 and its results of operations for the three and six months ended June 30, 2023 and 2022 and cash flows for the six months ended June 30, 2023 and 2022. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and six month periods is also unaudited. The results of operations for the three and six months ended June 30, 2023, are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended December 31, 2022 included in its Annual Report on Form 10-K filed with the SEC on March 27, 2023. Our significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to revenue recognition, inventory valuation, the fair values of derivative liabilities, stock-based compensation expense, deferred royalty obligation, lease accounting, income taxes, and additional charges as a result of, or that are associated with, any restructuring initiative as well as impairment and related charges. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates. Segments The Company’s chief operating decision maker is its Chairman and Chief Executive Officer. The Chairman and Chief Executive Officer reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company’s resources. Accordingly, the Company has determined that it operates in one segment. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivables. The Company’s cash is deposited with high credit quality financial institutions. At times such deposits may be in excess of the Federal Depository Insurance Corporation insured limits. Selling, General and Administrative Expense Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs. The Company expenses the cost of advertising, including promotional expenses, as incurred. Advertising expenses were $ 4.1 million and $ 6.9 million for the three and six months ended June 30, 2023. The Company incurred $ 1.4 million and $ 3.5 million for the three and six months ended June 30, 2022. Impairment of Long-Lived Assets Long-lived assets consist of property and equipment and right of use assets. The Company reviews property and equipment and right of use assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable or that the useful life is shorter than the Company had originally estimated. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future undiscounted cash flows which the asset or asset group is expected to generate. If the asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. If the useful life is shorter than originally estimated, the Company amortizes the remaining carrying value over the new shorter useful life. Recently Adopted Accounting Pronouncements In June 2016 the FASB issued Accounting Standard Update ("ASU") 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This introduces new methodology for recognition of credit losses - the current expected credit loss (“CECL”) method. The CECL method requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument, unless the company elects to recognize such instruments at fair value with changes in profit and loss. The Company adopted this guidance as of January 1, 2023. The adoption did not have a material impact to the Company or its disclosures. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 3. Fair Value Measurements The following table summarizes the fair value of the Company’s financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): June 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Common stock warrant liabilities $ — $ — $ 68 $ 68 Derivative liability - Deferred royalty obligation — — 2,660 2,660 Derivative liability - Oaktree term loan — — - - Total financial liabilities $ — $ — $ 2,728 $ 2,728 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Common stock warrant liabilities $ — $ — $ 261 $ 261 Derivative liability - Deferred royalty obligation — — 11,000 11,000 Derivative liability - Oaktree term loan — — 560 560 Total financial liabilities $ — $ — $ 11,821 $ 11,821 The following table summarizes the change in the fair value of the common stock warrant liabilities for the six months ended June 30, 2023 (in thousands): Beginning balance as of December 31, 2022 $ 261 Changes in fair value ( 193 ) Ending balance as of June 30, 2023 $ 68 The following table summarizes the change in the estimated fair value of the Company’s derivative liabilities for the six months ended June 30, 2023 (in thousands): Beginning balance as of December 31, 2022 $ 11,560 Change in fair value of derivatives - Deferred royalty obligation ( 8,340 ) Change in fair value of derivatives - Oaktree term loan ( 560 ) Ending balance as of June 30, 2023 $ 2,660 Fair values of the Company’s common stock warrants and the derivative liabilities are based on significant inputs not observed in the market, and thus represent a Level 3 measurement. The Senior Credit Agreement with Oaktree contains embedded derivatives requiring bifurcation as a derivative instrument. The derivative liability related to the Oaktree term loan is netted with the term loan in the consolidated financial statements (see Note 6 for additional details). The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of other income (expense), net. The fair value of the embedded derivative liabilities associated with the term loan was estimated using a probability weighted discounted cash flow model to measure the fair value. This involves significant Level 3 inputs and assumptions including an (i) estimated probability and timing of a change in control and event of default, and (ii) our risk-adjusted discount rate. The embedded derivative liability associated with our deferred royalty obligation (see Note 8) is measured at fair value using an option pricing Monte Carlo simulation model and is netted with the deferred royalty obligation in the consolidated financial statements. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of other expense, net. The assumptions used in the option pricing Monte Carlo simulation model include:(i) the probability-weighted net sales of Trudhesa; (ii) our risk-adjusted discount rate; (iii) our cost of debt; and (iv) the probability of a change in control and event of default occurring during the term of the instrument. The effect of an increase or decrease of 5 % of the probability of (i) a change in control, (ii) event of default and (iii) forecast net sales of Trudhesa, would result in a loss of $ 0.1 million or a gain of $ 0.6 million, respectively. The decrease in the fair value of the embedded derivative liability at June 30, 2023 was based on changes in the expectations of timing and probability of occurrence an event of default and to a lesser extent, a change in control. Pursuant to the July 2021 loan and security agreement with Oxford Finance LLC and Silicon Valley Bank (the "Loan Agreement"), the Company issued common stock warrants (see Note 8). The Company's warrants are not indexed to the Company’s common stock in the manner contemplated by ASC 815-40 because the warrant provides for an adjustment to the exercise price upon an acquisition. The Warrants were measured at fair value at inception and are subsequently remeasured at each reporting date with changes in fair value recognized as a component of other income (expense), net in the consolidated statement of operations and other comprehensive loss. The Company determined the fair value of the common stock warrants using the Black-Scholes-Merton option pricing model based on significant unobservable inputs. The significant unobservable inputs used in the fair value measurement of the warrant liabilities is the volatility rate which is based on the historical volatility of a set of peer companies, that are publicly traded. |
Corporate Restructuring
Corporate Restructuring | 6 Months Ended |
Jun. 30, 2023 | |
Restructuring and Related Activities [Abstract] | |
Corporate Restructuring | 4. Corporate Restructuring On February 22, 2023, the Company announced a strategic update and corporate restructuring (the “Restructuring”) to reprioritize spend to capitalize on the continued positive momentum in payor and prescriber uptake of Trudhesa and halt research and development efforts on product candidates including INP105 to address acute agitation and aggression in autism spectrum disorder. As part of the Restructuring, the Company reduced headcount by 16 % through a reduction in its workforce. The reduction in workforce was completed by March 31, 2023. The Company incurred the following Restructuring charges consisting of winding down costs, exit and other related costs, impairments and write-offs of long-lived assets, and severance and employee-related costs (in thousands): Six Months Ended Severance and employee-related costs $ 1,007 Long-lived asset impairments and write-offs 415 Supplemental one-time termination charges 59 Total $ 1,481 The Company estimated that it will incur total cash expenses of approximately $ 1.0 million related to the Restructuring of which $ 0.8 million was paid in the first half of 2023. The cash payments were primarily comprised of severance and other related costs. The Company also completed an evaluation of the impact of the Restructuring on the carrying value of its long-lived assets, such as property and equipment. This process includes evaluating the estimated remaining lives, significant changes in the use, and potential impairment charges related to its long-lived assets. Based on its evaluation, the Company determined that certain of its long-lived assets were impaired as of March 31, 2023, and it recognized an impairment charge o f $ 0.4 million rela ted to its long-lived assets for the six months ended June 30, 2023. The Company may incur additional costs not currently contemplated due to events that may occur because of, or that are associated with, the Restructuring. The following table summarizes the activity related to the restructuring liabilities included in accrued liabilities on the condensed consolidated balance sheet associated with our restructuring initiatives for the six months ended June 30, 2023 (in thousands): June 30, Balance as of December 31, 2022 $ — Restructuring, impairment and related charges 1,481 Cash payments ( 789 ) Noncash activities ( 472 ) Balance as of June 30, 2023 $ 220 |
Balance Sheet Components
Balance Sheet Components | 6 Months Ended |
Jun. 30, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Balance Sheet Components | 5. Balance Sheet Components Inventory Inventories consisted of the following (in thousands): June 30, December 31, Raw materials $ 4,989 $ 2,461 Work-in-process 4,647 4,191 Finished goods 659 3,334 Total inventories 10,295 9,986 Less: long-term inventories ( 3,310 ) ( 1,559 ) Total current inventories $ 6,985 $ 8,427 Inventory amounts written down to net realizable value in the consolidated statements of operations and comprehensive loss included a charge of $ 0.2 million and $ 1.0 million to cost of goods sold during the three and six months ended June 30, 2023, related to excess and obsolescence reserves associated with Trudhesa. The Company classifies its inventories based on its anticipated levels of sales, any inventory in excess of its normal operating cycle is classified as long-term within Other Assets on its consolidated balance sheets. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, Other prepaids $ 2,261 $ 1,587 Prepaid insurance 1,264 1,036 Other current assets 418 649 Tax refund receivable 13 12 Total prepaid expenses and other current assets $ 3,956 $ 3,284 Accrued Liabilities Accrued liabilities consisted of the following (in thousands): June 30, December 31, Accrued sales discounts and allowances $ 4,567 $ 3,376 Accrued compensation 3,868 5,287 Accrued professional services 2,387 1,808 Accrued other liabilities 892 1,662 Accrued construction in progress 104 370 Total accrued liabilities $ 11,818 $ 12,503 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | . Commitments and Contingencies Legal Proceedings From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company did not accrue any costs as of June 30, 2023 and December 31, 2022, as no contingent liabilities were deemed to be probable. |
Leases
Leases | 6 Months Ended |
Jun. 30, 2023 | |
Leases [Abstract] | |
Leases | 7. Leases Real Estate Leases In April 2022 the Company entered into a non-cancelable operating lease for 8,045 square feet of office space. Rent is payable monthly, increasing by appro ximately 2.5 % each year. The term of the lease is 127 months, and commenced in the first quarter of 2023. Upon commencement, the Company rec orded a right-of-use asset and a lease liability on the Condensed Consolidated Balance Sheet. In September 2017, the Company entered into a non-cancelable operating lease for 11,256 square feet of office and laboratory space. Rent is payable monthly, increasing by approximately 3 % each year. The initial term of the lease was 3 years and the Company renewed the lease for an additio nal four years with an expiration date of August 31, 2024 . Commercial Fleet Leases During 2022 and in first half of 2023, the Company took delivery of a portion of its commercial car fleet for its salesforce. Each commercial fleet lease has a term of 12 months including options to renew for a total of 54 months, we believe a total of 36 months is deemed reasonable to exercise. In addition, the Company can terminate the vehicle leases at any time without a significant penalty. For the discount rate used in the commercial fleet lease, the Company used the weighted-average rate implicit in the commercial fleet leases. As of June 30, 2023, the Company was not party to any finance leases. The following table reconciles the Company’s undiscounted operating lease cash flows to its operating lease liability (in thousands): June 30, 2023 Remaining 2023 $ 999 2024 1,716 2025 807 2026 315 2027 and thereafter 1,830 Total undiscounted cash flows 5,667 Less: imputed interest ( 1,195 ) Total lease liabilities 4,472 Less: current portion ( 1,728 ) Lease liabilities $ 2,744 The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows: June 30, 2023 Weighted average remaining lease term (years) 4.9 Weighted average discount rate 7.8 % Operating lease expense was $ 0.5 and $ 0.3 million for the three months ended June 30, 2023 and 2022, respectively and $ 1.0 and $ 0.6 million for the six months ended June 30, 2023 and 2022, respectively. Variable lease expense was $ 0.1 and $ 0.2 million for operating leases during the three and six months ended June 30, 2022. Rent expense recognized for short term leases was $ 0.1 and $ 0.2 million for the three and six months ended June 30, 2022. The Company did not incur any variable lease expense and rent expense for short term leases for the three and six months ended June 30, 2023. |
Debt
Debt | 6 Months Ended |
Jun. 30, 2023 | |
Debt Disclosure [Abstract] | |
Debt | 8. Long-Term Obligations Oaktree Loan and Security Agreement On March 17, 2022 (“Closing Date”), the Company entered into a Senior Credit Agreement with Oaktree Fund Administration, LLC as administrative agent, and the lenders party thereto (collectively “Oaktree”) under which it borrowed $ 50.0 million. The term loan has a maturity date of March 17, 2027 , initially bearing interest at the Secured Overnight Financing Rate (“SOFR”) + 8.75 % (with a SOFR floor of 1.00%). Once Trudhesa achieves at least $ 125.0 million in net sales over a trailing 12-month period, interest will step down to SOFR + 8.00 % (with a SOFR floor of 1.00%). The Company is required to make quarterly interest-only payments until the fourth anniversary of the Closing Date, after which the Company is required to make quarterly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. Prepayments of the loan, in whole or in part, will be subject to early prepayment fee which declines each year until the fourth anniversary date of the Closing Date, after which no prepayment fee is required. The Company is also required to pay an exit fee upon any payment or prepayment equal to 2.0 % of the aggregate principal amount of the loans funded under the Senior Credit Agreement. The Senior Credit Agreement contains customary representations, warranties and events o f default. If the Company defaults under its Senior Credit Agreement, the lenders may accelerate all of the Company's repayment obligations and take control of its pledged assets. The lenders could declare the Company in default under its debt obligation upon the occurrence of any event that the lenders interpret as having a material adverse effect as defined under the Senior Credit Agreement and the Revenue Interest Financing Agreement, thereby requiring the Company to repay the loans immediately or to attempt to reverse the lenders’ declaration through negotiation or litigation. Among other loan covenant requirements, the Senior Credit Agreement also requires the Company to provide an audit opinion of its annual financial statements not subject to any "going concern" or like qualification or exception or explanatory paragraph of going concern footnote. On March 22, 2023, the Company entered into a letter agreement with Oaktree in connection with its Senior Credit Agreement, to obtain a waiver from Oaktree for any default or event of default arising from the going concern explanatory paragraph included in the report of its Independent Registered Public Accounting Firm on its audited consolidated financial statements for the year ended December 31, 2022. Under the Senior Credit Agreement, the Company is subject to a minimum liquidity requirement of $ 12.5 million unrestricted cash balance at all times. The Company identified a number of embedded derivatives that require bifurcation from the term loan and that were separately accounted for in the consolidated financial statements as one compound derivative liability. Certain of these embedded features include change in control provisions, events of default and contingent rate increases and were determined to qualify as an embedded derivative under ASC 815-40. The embedded derivative and the term loan obligation have been netted to result in a net loan obligation and is classified as a Level 3 financial liability in the fair value hierarchy as of June 30, 2023. The fair value of the embedded derivative liabilities associated with the term loan were estimated using the discounted cash flow method under the income approach. This involves significant Level 3 inputs and assumptions including an estimated probability and timing of a change in control and events of default (see Note 3 for additional details). The Company re-evaluates this assessment each reporting period and records any gains or losses in other income (expense). The initial recognition of the embedded derivative liability upon issuance of the Oaktree term loan was $ 0.4 million and was included in the term loan obligation in the consolidated Balance Sheets. At June 30, 2023 and December 31, 2022 the fair value of the embedded derivative liability was zero and $ 0.6 million, respectively. In connection with the issuance of the term loan, the Company recorded debt discount and debt issuance costs of $ 2.9 million. The discount and issuance costs are amortized over the life of the term loan. Interest expense for the three months ended June 30, 2023 and 2022 was $ 1.9 million and $ 1.4 million, respectively, and for the six months ended June 30, 2023 and 2022 was $ 3.8 million and $ 1.6 million, respectively, and is inclusive of non-cash amortization of the debt discount and debt issuance costs and accretion of final payment. The fair value of th e term loan at June 30, 2023 and December 31, 2022 was $ 53.9 million and $ 51.9 million, respectively. A portion of the loan proceeds were used to repay in full the $ 32.9 million aggregate principal amount (including the prepayment fee and final payment fee) of loans outstanding owed to Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB” and together with Oxford, the “Prior Lenders”) by the Company in the first quarter of 2022. As of June 30, 2023, the Company was in compliance with all applicable covenants, however, the Company violated the minimum liquidity covenant prior to and as of the date of issuance of these interim financial statements and as such the Term Loan has been classified as a current liability on the June 30, 2023 condensed consolidated balance sheet. Deferred Royalty Obligation On March 17, 2022, the Company entered into a Revenue Interest Financing Agreement (“RIF” or “Deferred Royalty Obligation”) with certain purchasers party thereto (collectively “Purchasers”) and Oaktree Fund Administration, LLC as administrative agent, pursuant to which the Company sold to the Purchasers the right to receive payments from us at a tiered percentage (the “Applicable Tiered Percentage”), of future net revenues of Trudhesa, including worldwide net product sales and upfront payments, and milestones, (collectively, “the Revenue Interests”). Under the terms of the agreement, the Company received $ 50.0 million (“Investment Amount”), less transaction expenses, in exchange for tiered royalty payments on worldwide net sales from Trudhesa, as follows: 7.75% on annual United States net sales up to $150.0 million; 4.75% on annual United States net sales between $150 million and $300 million; 0.75% on annual United States net sales greater than $300.0 million; and 10% of any upfront payments, milestone payments and royalties received by us from licensing or partnerships relating to Trudhesa outside the United States. The Purchaser’s rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received payments equal to 175% of the funded portion of the Investment Amount including the aggregate of all payments made to the Purchasers as of such date, unless the Revenue Interest Financing Agreement is earlier terminated. If the Purchasers have not received payments equal to the 175% of the funded portion of the Investment Amount by the nine-year anniversary of the initial closing date, among other things, the Company shall pay the Purchasers an amount equal to the funded portion of the Investment Amount plus a specific annual rate of return less payments previously received. Under the RIF, the Company has an option (the “Call Option”) to repurchase future Revenue Interests at any time until the third anniversary of the Closing Date upon advance written notice. Additionally, the Purchasers have an option (the “Put Option”) to terminate the RIF and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price is (i) as of any date before the one-year anniversary of the Closing Date, an amount equal to (a) 1.25 multiplied by (b) the Investment Amount, (ii) as of any date on or after the one-year anniversary of the Closing Date and before the two-year anniversary of the Closing Date, an amount equal to (a) 1.40 multiplied by (b) the Investment Amount, (iii) as of any date on or after the two-year anniversary of the Closing Date and before the three-year anniversary of the Closing Date, an amount equal to (a) 1.55 multiplied by (b) the Investment Amount, and (iv) as of any date on or after the three-year anniversary of the Closing Date, an amount equal to (a) 1.75 multiplied by (b) the Investment Amount, in each case net of the sum of any payments received by the Purchasers prior to such Put Option Closing Date or Call Option Closing Date, as applicable. If the Purchasers have not received 100% of the Investment Amount by February 15, 2027, the first tier royalty rate will be subject to an increase from 7.75 % to 10.75 %. As of June 30, 2023, the Company has made $ 1.2 million in payments to the Purchasers. The Company's obligations under the RIF are secured, subject to customary permitted liens and other agreed upon exceptions and subject to an intercreditor agreement with Oaktree Fund Administration, LLC, as administrative agent for the lenders under the Senior Credit Agreement, by a perfected security interest in (i) accounts receivable arising from net sales of Trudhesa and (ii) intellectual property that is claiming or covering Trudhesa, or any method of using, making or manufacturing Trudhesa, including regulatory approvals, clinical data and all other Trudhesa assets. The Company evaluated the terms of the deferred royalty obligation and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, the Company accounted for the transaction as long-term debt recorded at amortized cost using the effective interest method. The Company further evaluated the terms of the debt and determined that the Put Options under the RIF that are exercisable by Purchasers upon certain contingent events were determined to be embedded derivatives requiring bifurcation and separately accounted for as a single compound derivative instrument (see Note 3). The Put Option has been determined to qualify as an embedded derivative under ASC 815-40. The embedded derivative and the deferred royalty obligation have been netted to result in a net deferred royalty obligation as of June 30, 2023 and December 31, 2022. The embedded derivative is classified as a Level 3 financial liability in the fair value hierarchy. The Company determined the fair value of the derivative using an option pricing Monte Carlo simulation model taking into account the probability of change of control or event of default occurring and potential repayment amounts and timing of such payments that would result under various scenarios, as further described in Note 3, “Fair Value of Financial Instruments”. The Company recorded the initial fair value of the derivative liability of $ 1.5 million which was included in the deferred royalty obligation in the consolidated Balance Sheet. The Company remeasures the derivative liability to fair value each reporting period until the termination of the RIF. At June 30, 2023 and December 31, 2022 the fair value of the derivative liability is $ 2.7 million and $ 11.0 million, respectively. The effective interest rate as of June 30, 2023 was 9.1 %. In connection with the deferred royalty obligation, we incurred debt issuance costs totaling $ 1.4 million. Debt issuance costs have been netted against the deferred royalty obligation and are being amortized over the estimated term of the debt using the effective interest method, adjusted on a prospective basis for changes in the underlying assumptions and inputs. The assumptions used in determining the expected repayment term of the obligation and amortization period of the issuance costs requires that we make estimates that could impact the short and long-term classification of these costs, as well as the period over which these costs will be amortized. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success, and sales price, among others. To the extent such payments are greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the deferred royalty obligations and the effective interest rate. Interest expense recognized for the three months ended June 30, 2023 and 2022 was $ 1.2 million and $ 2.0 million, and for the six months ended June 30, 2023 and 2022 was $ 2.5 million and $ 2.4 million respectively . The fair value of the deferred royalty obligation at June 30, 2023 and December 31, 2022 is $ 51.7 million and $ 48.9 million, respectively, inclusive of the fair value of the derivative liability. The Senior Credit Agreement contains cross-default provisions with the Deferred Royalty Obligation, so that if a default occurs under any one of these agreement, the lenders could declare a default. The violation of the minimum liquidity covenant under the Senior Credit Agreement prior to and as of the date of the issuance of these interim financial statements, triggered the default of the Deferred Royalty Obligation. As of June 30, 2023, the Deferred Royalty Obligation has been classified as a current liability in conjunction with the event of default occurring under the Senior Credit Agreement. Oxford and Silicon Valley Bank Term Loan In July 2021, the Company entered into the Loan Agreement with the “Prior Lenders”, to lend the Company up to an aggregate of $ 50.0 million in a series of term loans (the “Term Loan”). The term loans accrued interest at the greater of (i) 7.95% or (ii) the sum of (a) the greater of (1) the thirty (30) day U.S. LIBOR or (2) 0.11%, plus (b) 7.84% and were subject to a prepayment fee of 1.0 % to 3.0 % depending upon when the prepayment occurs. On repayment of the Term Loans, the Company was required to make a final payment fee to the Prior Lenders equal to 6.5 % of the original principal amount of the Term Loans. On March 17, 2022, upon entering into the Senior Credit Agreement, the Company repaid the $ 30.0 million of outstanding principal, interest, including prepayment and final payment fees owed under the Loan Agreement to the Prior Lenders. The Company recorded a loss of $ 3.3 million on the early extinguishment of debt related to the unamortized debt discount associated with the fair value of the warrants, final payment fee, and unamortized debt issuance costs. The loss on early extinguishment was recognized as a component of interest expense, net in the consolidated statement of operations and other comprehensive loss. Interest expense for the three and six months ended June 30, 2022 was $ 0.7 million and was inclusive of non-cash amortization in the amount of $ 0.2 million related to the amortization of the debt issuance costs and accretion of final payment. In connection with entering into the Loan Agreement and borrowings under the agreement, the Company issued warrants to purchase 71,522 and 23,166 , shares of its common stock, respectively, to the Prior Lenders at a per share exercisable price of $ 8.39 per share and $ 12.95 per share, respectively, all with ten year terms. |
Common Stock
Common Stock | 6 Months Ended |
Jun. 30, 2023 | |
Equity [Abstract] | |
Common Stock | 9. Common Stock Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No cash dividends have been declared by the board of directors from inception. The Company has reserved the following shares of common stock for issuance, on an as-converted basis, as follows: June 30, December 31, Stock incentive plans 7,776,500 6,351,263 Exercise of common stock warrants 94,688 94,688 Total 7,871,188 6,445,951 Open Market Sales Agreement In May 2022, the Company entered into a sales agreement with Cowen and Company, LLC, as a sales agent, pursuant to which the Company may offer and sell shares of its common stock, from time to time, up to an aggregate amount of gross sales proceeds of $ 50.0 million through an at-the-market Program (the "2022 ATM Program"), under the 2022 Shelf Registration Statement. As of June 30, 2023, $ 45.0 million in shares of common stock remain eligible for sale under the 2022 ATM Program. |
Stock Incentive Plans
Stock Incentive Plans | 6 Months Ended |
Jun. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Stock Incentive Plans | 10. Stock Incentive Plans As of June 30, 2023, the Com pany’s equity incentive plans authorized a total of 7,776,500 shares, of which 2,894,973 shares are available for future grant, and 4,881,927 shares are outstanding. The Company’s 2021 Stock Incentive Plan, (the "2021 Plan"), provides for annual increase in the number of shares that may be issued under the 2021 Plan automatically on January 1 of each of 2022 through 2031 by the lesser of (a) 5 % of the total number of outstanding shares of all classes of its common stock on each December 31 and (b) a number as may be determined by its board of directors. The Company’s Employee Stock Purchase Plan (the "ESPP"), provides for annual increase in the number of shares that may be issued under the 2021 Plan automatically on January 1 of each of 2022 through 2031 by the lesser of (a) 5 % of the total number of outstanding shares of all classes of its common stock on each December 31 and (b) a number as may be determined by its board of directors. Effective January 1, 2023, the 2021 Plan and ESPP reserves increased by 1,186,965 shares and 237,393 shares, respectively. Changes in shares available for grant under the 2021 Plan during the six months ended June 30, 2023 were as follows: Shares Available for Grant Shares available for grant at December 31, 2022 1,837,854 2021 Plan reserve increase January 1, 2023 1,186,965 ESPP reserve increase January 1, 2023 237,393 Options and restricted units granted ( 1,193,143 ) Options and restricted units forfeited, cancelled, or expired 825,904 Shares available for grant at June 30, 2023 2,894,973 Stock-Based Compensation Expense Stock-based compensation expense recognized was as follows (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Cost of goods sold $ 59 $ 23 $ 76 $ 54 Research and development 54 199 224 610 Selling, general and administrative 986 1,357 2,118 2,710 Total stock-based compensation expense $ 1,099 $ 1,579 $ 2,418 $ 3,374 Stock Option Activity All stock option grants are awarded at fair value on the date of grant. The fair value of stock options is estimated using the Black-Scholes option pricing model and stock-based compensation is recognized on a straight-line basis over the requisite service period. Stock options granted generally become exercisable over a four-year period from the grant date. Stock options generally expire 10 years after the grant date. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company's common stock for those stock options that had exercise prices lower than the fair value of the Company's common stock at June 30, 2023. A summary of the Company’s stock option activity under its stock option plans was as follows (in thousands, except share and per share data and years): Options Outstanding Number of Weighted Remaining Aggregate Balance — December 31, 2022 4,275,909 $ 8.08 7.5 $ 1,038 Authorized — Granted 1,145,643 2.23 Exercised ( 2,748 ) 1.97 Cancelled ( 789,777 ) 5.45 Balance — June 30, 2023 4,629,027 $ 6.82 7.5 $ — Exercisable — June 30, 2023 2,491,654 $ 7.10 6.3 $ — As of June 30, 2023, there was $ 8.9 million of total unrecognized compensation cost related to unvested options that are expected to vest. The cost is expected to be recognized over a weighted-average period of 2.4 years. The fair value of stock option awards granted to employees was estimated at the date of grant usin g a Black-Scholes-Merton option pricing model with the following assumptions: Three Months Ended Six Months Ended 2023 2022 2023 2022 Expected term (in years) 6.1 6.1 6.1 6.1 Expected volatility 71.3 %- 71.4 % 72.7 %- 73.4 % 70.7 %- 71.4 % 72.7 %- 73.4 % Risk-free interest rate 3.38 % - 3.94 % 2.79 % - 3.33 % 3.38 % - 3.95 % 1.70 % - 3.33 % Expected dividends — — — — Restricted Stock Units The Company’s Restricted Stock Units ("RSUs") are considered non-vested share awards and require no payment from the employee. For each RSU, employees receive one share of common stock at the end of the vesting period. The employee can elect to receive the one share of common stock net of taxes or pay for taxes separately and receive the entire share. The fair value of a restricted stock unit award at the grant date is equal to the market price of the Company's common stock on the grant date. Compensation expense is recorded based on the market price of the Company’s common stock on the grant date and is recognized on a straight-line basis over the requisite service period. As of June 30, 2023, there was less than $ 0.1 million of total unrecognized compensation cost related to the Company's RSUs that are expected to vest. These costs are expected to be recognized over a weighted-average period of 0.9 years. During 2021, the Compensation Committee of the Board of Directors approved the Trudhesa Launch Equity Incentive Plan for awards of performance-based restricted stock units ("PSUs") to certain senior executives of the Company. Each award reflects a target number of shares (“Target Shares”) that may be issued to the award recipient. These awards may be earned upon the completion of two-year performance periods ending December 31, 2022, and December 31, 2023. Whether units are earned at the end of the performance period will be determined based on the achievement of certain revenue targets over the performance period. The PSUs also include a performance objective relating to total shareholder return (“TSR”). TSR reflects the change in the value of the Company’s common stock over each performance period. Depending on the revenue achieved and the TSR during the two-year performance periods, the actual number of shares that a grant recipient receives at the end of the performance period may range from 0 % to 125 % of the Target Shares granted for the 2022 performance period and 0 % to 150 % of the Target Shares granted for the 2023 performance period. In the period it becomes probable that the minimum revenue threshold specified in the award will be achieved, we recognize expense for the proportionate share of the total fair value of the PSUs related to the vesting period that has already lapsed for the shares expected to vest and be released. The remaining fair value of the shares expected to vest and be released is expensed on a straight-line basis over the balance of the vesting period. In the event the Company determines it is no longer probable that we will achieve the minimum threshold specified in the award, we reverse all of the previously recognized compensation expense in the period such a determination is made. The fair value of the Target Shares and restricted stock awards are based on the fair value of the underlying shares on the date of grant. The fair value of the portion of the Target Shares that relate to a relative TSR performance objective was determined using a Monte Carlo simulation analy sis to estimate the total shareholder return ranking of the Company among a peer group over the remaining performance periods. The expected volatility of the Company’s common stock at the date of grant was estimated based on the average historical volatilities for comparable publicly traded pharmaceutical companies. The Company used an expected dividend yield of zero . The risk-free interest rate assumption was based on observed interest rates consistent with the approximate two-year performance measure ment period. The fair value of PSUs granted to employees was estimated at the date of grant using the following assumptions: December 31, 2021 Contractual term (in years) 2.1 Expected volatility 0.83 % Risk-free interest rate 0.70 % Expected dividends — There were no PSUs that vested during the six months ended June 30, 2023 and 205,000 and 237,500 PSUs are outstanding as of June 30, 2023 and December 31, 2022, respectively. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 11. Income Taxes To calculate the interim tax provision, at the end of each interim period the Company estimates the annual effective tax rate and applies that to its quarterly earnings from continuing operations. The effect of changes in the enacted tax laws or rates is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and judgments including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in foreign jurisdictions, permanent differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained, or the tax environment changes. The Company’s effective tax rate for the three and six months ended June 30, 2023 and 2022 differs from the U.S. statutory rate due to ongoing cumulative losses and the related valuation allowance. During the three and six months ended June 30, 2023, the Company reported U.S. pre-tax losses, consistent with prior years to date. The Company has not yet been able to establish a sustained level of profitability in the U.S. or other sufficient significant positive evidence to conclude that its U.S. deferred tax assets are more likely than not to be realized. Therefore, the Company continues to maintain a valuation allowance against its U.S. deferred tax assets. |
Defined Contribution Plan
Defined Contribution Plan | 6 Months Ended |
Jun. 30, 2023 | |
Retirement Benefits [Abstract] | |
Defined Contribution Plan | 12. Defined Contribution Plan The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation on a pre-tax or after-tax basis. The Company makes discretionary matching contributions of up to 4 % of a participating employee’s salary. For the three and six months ended June 30, 2023, the amount expensed under the plan was $ 0.2 million and $ 0.5 million respectively. For the three and six months ended June 30, 2022, the amount expensed under the plan was $ 0.2 million and $ 0.4 million respectively. |
Net Loss Per Share
Net Loss Per Share | 6 Months Ended |
Jun. 30, 2023 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | 13. Net Loss Per Share The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Six Months Ended 2023 2022 Stock options to purchase common stock 4,629,027 4,135,901 Non-vested RSUs and PSUs 252,500 485,571 Warrants to purchase common stock 94,688 94,688 Total 4,976,215 4,716,160 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Consolidation | Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and rules and regulations of the SEC for interim financial reporting. The condensed consolidated financial statements include the operations of Impel Pharmaceuticals Inc., and its wholly owned Australian subsidiary. All intercompany balances and transactions have been eliminated upon consolidation. The condensed consolidated balance sheet as of June 30, 2023, the condensed consolidated statements of operations and comprehensive loss, and changes in stockholders’ (deficit) equity for the three and six months ended June 30, 2023 and 2022 and cash flows for the six months ended June 30, 2023 and 2022 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position as of June 30, 2023 and its results of operations for the three and six months ended June 30, 2023 and 2022 and cash flows for the six months ended June 30, 2023 and 2022. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and six month periods is also unaudited. The results of operations for the three and six months ended June 30, 2023, are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended December 31, 2022 included in its Annual Report on Form 10-K filed with the SEC on March 27, 2023. Our significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to revenue recognition, inventory valuation, the fair values of derivative liabilities, stock-based compensation expense, deferred royalty obligation, lease accounting, income taxes, and additional charges as a result of, or that are associated with, any restructuring initiative as well as impairment and related charges. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates. |
Segments | Segments The Company’s chief operating decision maker is its Chairman and Chief Executive Officer. The Chairman and Chief Executive Officer reviews financial information on an aggregate basis for the purposes of evaluating financial performance and allocating the Company’s resources. Accordingly, the Company has determined that it operates in one segment. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivables. The Company’s cash is deposited with high credit quality financial institutions. At times such deposits may be in excess of the Federal Depository Insurance Corporation insured limits. |
Selling, General and Administrative Expense | Selling, General and Administrative Expense Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs. The Company expenses the cost of advertising, including promotional expenses, as incurred. Advertising expenses were $ 4.1 million and $ 6.9 million for the three and six months ended June 30, 2023. The Company incurred $ 1.4 million and $ 3.5 million for the three and six months ended June 30, 2022. |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets Long-lived assets consist of property and equipment and right of use assets. The Company reviews property and equipment and right of use assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable or that the useful life is shorter than the Company had originally estimated. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future undiscounted cash flows which the asset or asset group is expected to generate. If the asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. If the useful life is shorter than originally estimated, the Company amortizes the remaining carrying value over the new shorter useful life. |
Recent Accounting Pronouncements | Recently Adopted Accounting Pronouncements In June 2016 the FASB issued Accounting Standard Update ("ASU") 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This introduces new methodology for recognition of credit losses - the current expected credit loss (“CECL”) method. The CECL method requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument, unless the company elects to recognize such instruments at fair value with changes in profit and loss. The Company adopted this guidance as of January 1, 2023. The adoption did not have a material impact to the Company or its disclosures. |
Emerging Growth Company Status | Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Summary of Fair Value, Liabilities Measured on Recurring Basis | The following table summarizes the fair value of the Company’s financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): June 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Common stock warrant liabilities $ — $ — $ 68 $ 68 Derivative liability - Deferred royalty obligation — — 2,660 2,660 Derivative liability - Oaktree term loan — — - - Total financial liabilities $ — $ — $ 2,728 $ 2,728 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Common stock warrant liabilities $ — $ — $ 261 $ 261 Derivative liability - Deferred royalty obligation — — 11,000 11,000 Derivative liability - Oaktree term loan — — 560 560 Total financial liabilities $ — $ — $ 11,821 $ 11,821 |
Summary of Change in the Fair Value of the Common Stock Warrant Liabilities | The following table summarizes the change in the fair value of the common stock warrant liabilities for the six months ended June 30, 2023 (in thousands): Beginning balance as of December 31, 2022 $ 261 Changes in fair value ( 193 ) Ending balance as of June 30, 2023 $ 68 |
Schedule of Derivative Liabilities at Fair Value [Table Text Block] | The following table summarizes the change in the estimated fair value of the Company’s derivative liabilities for the six months ended June 30, 2023 (in thousands): Beginning balance as of December 31, 2022 $ 11,560 Change in fair value of derivatives - Deferred royalty obligation ( 8,340 ) Change in fair value of derivatives - Oaktree term loan ( 560 ) Ending balance as of June 30, 2023 $ 2,660 |
Corporate Restructuring (Tables
Corporate Restructuring (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Restructuring and Related Activities [Abstract] | |
Schedule of Restructuring Charges | The Company incurred the following Restructuring charges consisting of winding down costs, exit and other related costs, impairments and write-offs of long-lived assets, and severance and employee-related costs (in thousands): Six Months Ended Severance and employee-related costs $ 1,007 Long-lived asset impairments and write-offs 415 Supplemental one-time termination charges 59 Total $ 1,481 |
Summary of the activity related to the restructuring liabilities | The following table summarizes the activity related to the restructuring liabilities included in accrued liabilities on the condensed consolidated balance sheet associated with our restructuring initiatives for the six months ended June 30, 2023 (in thousands): June 30, Balance as of December 31, 2022 $ — Restructuring, impairment and related charges 1,481 Cash payments ( 789 ) Noncash activities ( 472 ) Balance as of June 30, 2023 $ 220 |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of Inventories | Inventories consisted of the following (in thousands): June 30, December 31, Raw materials $ 4,989 $ 2,461 Work-in-process 4,647 4,191 Finished goods 659 3,334 Total inventories 10,295 9,986 Less: long-term inventories ( 3,310 ) ( 1,559 ) Total current inventories $ 6,985 $ 8,427 |
Schedule of prepaid expenses and other current assets | Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, Other prepaids $ 2,261 $ 1,587 Prepaid insurance 1,264 1,036 Other current assets 418 649 Tax refund receivable 13 12 Total prepaid expenses and other current assets $ 3,956 $ 3,284 |
Schedule of accrued liabilities | Accrued liabilities consisted of the following (in thousands): June 30, December 31, Accrued sales discounts and allowances $ 4,567 $ 3,376 Accrued compensation 3,868 5,287 Accrued professional services 2,387 1,808 Accrued other liabilities 892 1,662 Accrued construction in progress 104 370 Total accrued liabilities $ 11,818 $ 12,503 |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Leases [Abstract] | |
ScheduleOfMaturitiesOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock | The following table reconciles the Company’s undiscounted operating lease cash flows to its operating lease liability (in thousands): June 30, 2023 Remaining 2023 $ 999 2024 1,716 2025 807 2026 315 2027 and thereafter 1,830 Total undiscounted cash flows 5,667 Less: imputed interest ( 1,195 ) Total lease liabilities 4,472 Less: current portion ( 1,728 ) Lease liabilities $ 2,744 |
Weighted average remaining lease term and the weighted average discount rate table text block | The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liability were as follows: June 30, 2023 Weighted average remaining lease term (years) 4.9 Weighted average discount rate 7.8 % Operating lease expense was $ 0.5 and $ 0.3 million for the three months ended June 30, 2023 and 2022, respectively and $ 1.0 and $ 0.6 million for the six months ended June 30, 2023 and 2022, respectively. Variable lease expense was $ 0.1 and $ 0.2 million for operating leases during the three and six months ended June 30, 2022. Rent expense recognized for short term leases was $ 0.1 and $ 0.2 million for the three and six months ended June 30, 2022. The Company did not incur any variable lease expense and rent expense for short term leases for the three and six months ended June 30, 2023. |
Common Stock (Tables)
Common Stock (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Equity [Abstract] | |
Schedule of Reserved Shares of Common Stock for Issuance, on an as-Converted Basis | The Company has reserved the following shares of common stock for issuance, on an as-converted basis, as follows: June 30, December 31, Stock incentive plans 7,776,500 6,351,263 Exercise of common stock warrants 94,688 94,688 Total 7,871,188 6,445,951 |
Stock Incentive Plans (Tables)
Stock Incentive Plans (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Changes in shares available for grant under the 2021 Plan | Changes in shares available for grant under the 2021 Plan during the six months ended June 30, 2023 were as follows: Shares Available for Grant Shares available for grant at December 31, 2022 1,837,854 2021 Plan reserve increase January 1, 2023 1,186,965 ESPP reserve increase January 1, 2023 237,393 Options and restricted units granted ( 1,193,143 ) Options and restricted units forfeited, cancelled, or expired 825,904 Shares available for grant at June 30, 2023 2,894,973 |
Schedule of Stock-Based Compensation Expense Recognized | Stock-based compensation expense recognized was as follows (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Cost of goods sold $ 59 $ 23 $ 76 $ 54 Research and development 54 199 224 610 Selling, general and administrative 986 1,357 2,118 2,710 Total stock-based compensation expense $ 1,099 $ 1,579 $ 2,418 $ 3,374 |
Stock Options [Member] | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Summary of the Company's Stock Option Activity under its Stock Option Plans | A summary of the Company’s stock option activity under its stock option plans was as follows (in thousands, except share and per share data and years): Options Outstanding Number of Weighted Remaining Aggregate Balance — December 31, 2022 4,275,909 $ 8.08 7.5 $ 1,038 Authorized — Granted 1,145,643 2.23 Exercised ( 2,748 ) 1.97 Cancelled ( 789,777 ) 5.45 Balance — June 30, 2023 4,629,027 $ 6.82 7.5 $ — Exercisable — June 30, 2023 2,491,654 $ 7.10 6.3 $ — |
Schedule of Fair Value of Stock Option Awards Granted to Employees | The fair value of stock option awards granted to employees was estimated at the date of grant usin g a Black-Scholes-Merton option pricing model with the following assumptions: Three Months Ended Six Months Ended 2023 2022 2023 2022 Expected term (in years) 6.1 6.1 6.1 6.1 Expected volatility 71.3 %- 71.4 % 72.7 %- 73.4 % 70.7 %- 71.4 % 72.7 %- 73.4 % Risk-free interest rate 3.38 % - 3.94 % 2.79 % - 3.33 % 3.38 % - 3.95 % 1.70 % - 3.33 % Expected dividends — — — — |
PSUs [Member] | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Schedule of Fair Value of Stock Option Awards Granted to Employees | The fair value of PSUs granted to employees was estimated at the date of grant using the following assumptions: December 31, 2021 Contractual term (in years) 2.1 Expected volatility 0.83 % Risk-free interest rate 0.70 % Expected dividends — |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders | The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Six Months Ended 2023 2022 Stock options to purchase common stock 4,629,027 4,135,901 Non-vested RSUs and PSUs 252,500 485,571 Warrants to purchase common stock 94,688 94,688 Total 4,976,215 4,716,160 |
Organization and Description _2
Organization and Description of Business - Additional Information (Details) - USD ($) $ in Thousands | 6 Months Ended | ||
Jun. 30, 2023 | Dec. 31, 2022 | Mar. 17, 2022 | |
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||
Proceeds from issuance or sale of equity, debt and warrants | $ 397,800 | ||
minimum liquidity covenant | 12,500 | ||
Cash | 15,162 | $ 60,654 | |
Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights | |||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||
Offering price of securities for, Offering, Issuance and Sale | 200,000 | ||
Senior Credit Agreement | |||
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||
Potential bridge financing facility | 20,000 | ||
Unrestricted cash balance | $ 12,500 | $ 12,500 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Debt Instrument [Line Items] | ||||
Advertising expenses | $ 4.1 | $ 1.4 | $ 6.9 | $ 3.5 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Liabilities: | ||
Total financial liabilities | $ 2,728 | $ 11,821 |
Warrant Liabilities [Member] | ||
Liabilities: | ||
Total financial liabilities | 68 | 261 |
Derivative liability - Deferred royalty obligation [Member] | ||
Liabilities: | ||
Total financial liabilities | 2,660 | 11,000 |
Derivative liability - Oaktree term loan [Member] | ||
Liabilities: | ||
Total financial liabilities | 0 | 560 |
Level 1 [Member] | ||
Liabilities: | ||
Total financial liabilities | 0 | 0 |
Level 1 [Member] | Warrant Liabilities [Member] | ||
Liabilities: | ||
Total financial liabilities | 0 | 0 |
Level 1 [Member] | Derivative liability - Deferred royalty obligation [Member] | ||
Liabilities: | ||
Total financial liabilities | 0 | |
Level 1 [Member] | Derivative liability - Oaktree term loan [Member] | ||
Liabilities: | ||
Total financial liabilities | 0 | |
Level 2 [Member] | ||
Liabilities: | ||
Total financial liabilities | 0 | 0 |
Level 2 [Member] | Warrant Liabilities [Member] | ||
Liabilities: | ||
Total financial liabilities | 0 | 0 |
Level 2 [Member] | Derivative liability - Deferred royalty obligation [Member] | ||
Liabilities: | ||
Total financial liabilities | 0 | |
Level 2 [Member] | Derivative liability - Oaktree term loan [Member] | ||
Liabilities: | ||
Total financial liabilities | 0 | |
Level 3 [Member] | ||
Liabilities: | ||
Total financial liabilities | 2,728 | 11,821 |
Level 3 [Member] | Warrant Liabilities [Member] | ||
Liabilities: | ||
Total financial liabilities | 68 | 261 |
Level 3 [Member] | Derivative liability - Deferred royalty obligation [Member] | ||
Liabilities: | ||
Total financial liabilities | 2,660 | 11,000 |
Level 3 [Member] | Derivative liability - Oaktree term loan [Member] | ||
Liabilities: | ||
Total financial liabilities | $ 0 | $ 560 |
Fair Value Measurements - Sum_2
Fair Value Measurements - Summary of Change in the Fair Value of the Common Stock Warrant Liabilities (Details) $ in Thousands | 6 Months Ended |
Jun. 30, 2023 USD ($) | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |
Beginning balance as of December 31, 2022 | $ 24 |
Ending balance as of March 31, 2023 | 24 |
Common Stock Warrant Liabilities [Member] | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |
Beginning balance as of December 31, 2022 | 261 |
Change in fair value | (193) |
Ending balance as of March 31, 2023 | $ 68 |
Fair Value Measurements - Chang
Fair Value Measurements - Change in the estimated fair value of the Company derivative liabilities (Details) $ in Thousands | 6 Months Ended |
Jun. 30, 2023 USD ($) | |
Fair Value Disclosures [Abstract] | |
Beginning balance as of December 31, 2022 | $ 11,560 |
Initial fair value of derivative liability - Deferred royalty obligation | 8,340 |
Change in fair value of derivatives | (560) |
Ending balance as of March 31, 2023 | $ 2,660 |
Fair Value Measurements (Additi
Fair Value Measurements (Additional Information) (Details) $ in Millions | 6 Months Ended |
Jun. 30, 2023 USD ($) | |
Fair Value Disclosures [Abstract] | |
Loss on unobservable input into the fair value estimate | $ 0.1 |
Gain on unobservable input into the fair value estimate | $ 0.6 |
Effect Of Increase Decrease In Probality Percentage related To Embedded Derivative Liability Remeasurement | 5% |
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | Derivative, Gain (Loss) on Derivative, Net |
Corporate Restructuring - Addit
Corporate Restructuring - Additional Information (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Feb. 22, 2023 | Jun. 30, 2023 | |
Restructuring Cost and Reserve [Line Items] | ||
Payment for Restructuring | $ 789 | |
Corporate Restructuring [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Reduction in workforce percentage | 16% | |
Total Estimated Cash Expenses for Restructuring | 1,000 | |
Payment for Restructuring | 800 | |
Impairment charges for long-lived assets | $ 400 |
Corporate Restructuring - Sched
Corporate Restructuring - Schedule of Restructuring Charges (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Restructuring and Related Activities [Abstract] | ||||
Severance and employee-related costs | $ 1,007 | |||
Long-lived asset impairments and write-offs | 415 | |||
Supplemental one-time termination charges | 59 | |||
Total | $ 0 | $ 1,481 |
Corporate Restructuring - Summa
Corporate Restructuring - Summary of the activity related to the restructuring liabilities (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Restructuring and Related Activities [Abstract] | ||||
Restructuring Reserve, Beginning Balance | $ 0 | |||
Restructuring, impairment and related charges | $ 0 | 1,481 | ||
Cash payments | (789) | |||
Noncash activities | (472) | |||
Restructuring Reserve, Ending Balance | $ 220 | $ 220 |
Balance Sheet Components - Sche
Balance Sheet Components - Schedule of Inventories (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Balance Sheet Related Disclosures [Abstract] | ||
Raw materials | $ 4,989 | $ 2,461 |
Work-in-process | 4,647 | 4,191 |
Finished goods | 659 | 3,334 |
Total inventories | 10,295 | 9,986 |
Less: long-term inventories | (3,310) | (1,559) |
Total current inventories | $ 6,985 | $ 8,427 |
Balance Sheet Components - Sc_2
Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Balance Sheet Related Disclosures [Abstract] | ||
Other prepaids | $ 2,261 | $ 1,587 |
Prepaid insurance | 1,264 | 1,036 |
Other current assets | 418 | 649 |
Tax refund receivable | 13 | 12 |
Total prepaid expenses and other current assets | $ 3,956 | $ 3,284 |
Balance Sheet Components (Addit
Balance Sheet Components (Additional Information) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2023 | Jun. 30, 2022 | |
Balance Sheet Related Disclosures [Abstract] | |||
Inventory Write-down | $ 1,070 | $ 0 | |
Inventory Write-Down | $ 200 | $ 1,000 |
Balance Sheet Components - Sc_3
Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Balance Sheet Related Disclosures [Abstract] | ||
Accrued sales discounts and allowances | $ 4,567 | $ 3,376 |
Accrued compensation | 3,868 | 5,287 |
Accrued professional services | 2,387 | 1,808 |
Accrued other liabilities | 892 | 1,662 |
Accrued construction in progress | 104 | 370 |
Total accrued liabilities | $ 11,818 | $ 12,503 |
Leases (Additional Information)
Leases (Additional Information) (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||||
Sep. 30, 2017 ft² | Apr. 30, 2022 ft² | Mar. 31, 2023 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Sep. 30, 2022 | |
Lessee, Lease, Description [Line Items] | |||||||||
Operating lease right-of-use assets | $ 4,442 | $ 3,132 | |||||||
Operating lease liability | 4,472 | ||||||||
Operating lease expense | $ 500 | $ 300 | $ 1,000 | $ 600 | |||||
Variable lease expense | $ 100 | 200 | |||||||
Rent expenses | $ 100 | $ 200 | |||||||
Real Estate Leases | |||||||||
Lessee, Lease, Description [Line Items] | |||||||||
Non cancelable operating lease area | ft² | 11,256 | 8,045 | |||||||
Percentage increase in rent payable monthly | 3% | 2.50% | |||||||
Initial term of the lease | 3 years | ||||||||
Renewed the lease | four years | 127 | |||||||
Operating lease expiration date | Aug. 31, 2024 | ||||||||
Commercial Fleet Leases | |||||||||
Lessee, Lease, Description [Line Items] | |||||||||
Initial term of the lease | 12 months | ||||||||
Lease renewal term | 54 months |
Leases - Companys undiscounted
Leases - Companys undiscounted operating lease cash flows to its operating lease liability (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Leases [Abstract] | ||
Remaining 2023 | $ 999 | |
2024 | 1,716 | |
2025 | 807 | |
2026 | 315 | |
2027 and thereafter | 1,830 | |
Total undiscounted cash flows | 5,667 | |
Less: imputed interest | (1,195) | |
Total lease liabilities | 4,472 | |
Less: current portion | (1,728) | $ (1,541) |
Lease liabilities | $ 2,744 | $ 1,573 |
Leases - Weighted average disco
Leases - Weighted average discount rate used to determine the operating lease liability (Details) | Jun. 30, 2023 |
Leases [Abstract] | |
Weighted average remaining lease term (years) | 4 years 10 months 24 days |
Weighted average discount rate | 7.80% |
Debt - Additional Information (
Debt - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | |||||
Mar. 17, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | Jul. 02, 2021 | |
Debt Instrument [Line Items] | |||||||
Debt instrument interest rate stated percentage | 9.10% | 9.10% | |||||
Long-term debt, description | The term loans accrued interest at the greater of (i) 7.95% or (ii) the sum of (a) the greater of (1) the thirty (30) day U.S. LIBOR or (2) 0.11%, plus (b) 7.84% | ||||||
Proceeds from issuance of debt | $ 1,400 | ||||||
Final Payment Percentage of Principal Amount Term Loan | 6.50% | ||||||
Common Stock Issued As Warrant Exercisable | 23,749,005 | 23,749,005 | 23,739,313 | ||||
Outstanding principal, interest and final payment amount | $ 0 | $ 32,853 | |||||
Loss on early extinguishment of debt | $ 0 | 3,251 | |||||
Fair value of derivative liability | $ 1,500 | 1,500 | |||||
Maximum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Prepayment fee for loan payment | 3% | ||||||
Minimum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Prepayment fee for loan payment | 1% | ||||||
Oaktree Loan and Security Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Short-term Non-bank Loans and Notes Payable | $ 50,000 | ||||||
Debt instrument, maturity date | Mar. 17, 2027 | ||||||
Oaktree Loan and Security Agreement [Member] | Tradhesa [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt, Weighted Average Interest Rate | 8% | ||||||
Net revenue | $ 125,000 | ||||||
Oaktree Loan and Security Agreement [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt, Weighted Average Interest Rate | 8.75% | ||||||
RIF | |||||||
Debt Instrument [Line Items] | |||||||
Interest expense | $ 1,200 | 2,000 | $ 2,500 | 2,400 | |||
Payment Purchase | 1,200 | 1,200 | |||||
Fair value of derivative liability | 2,700 | 2,700 | $ 11,000 | ||||
Fair value of deferred royalty obligation | 51,700 | 51,700 | 48,900 | ||||
RIF | One year anniversary | |||||||
Debt Instrument [Line Items] | |||||||
Future revenue interests | 1.25% | ||||||
RIF | Two year anniversary | |||||||
Debt Instrument [Line Items] | |||||||
Future revenue interests | 1.40% | ||||||
RIF | Three year anniversary | |||||||
Debt Instrument [Line Items] | |||||||
Future revenue interests | 1.55% | ||||||
RIF | Four year anniversary | |||||||
Debt Instrument [Line Items] | |||||||
Future revenue interests | 1.75% | ||||||
RIF | Maximum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Change in royalty rate | 10.75% | ||||||
RIF | Minimum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Change in royalty rate | 7.75% | ||||||
RIF | Tradhesa [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Future net Revenue Interests, descriptions | Under the terms of the agreement, the Company received $50.0 million (“Investment Amount”), less transaction expenses, in exchange for tiered royalty payments on worldwide net sales from Trudhesa, as follows: 7.75% on annual United States net sales up to $150.0 million; 4.75% on annual United States net sales between $150 million and $300 million; 0.75% on annual United States net sales greater than $300.0 million; and 10% of any upfront payments, milestone payments and royalties received by us from licensing or partnerships relating to Trudhesa outside the United States. | ||||||
Financing cost | $ 50,000 | ||||||
Senior Credit Agreement | |||||||
Debt Instrument [Line Items] | |||||||
Unrestricted cash balance | $ 12,500 | 12,500 | 12,500 | ||||
Prepayment fee for loan payment | 2% | ||||||
Amortization of Debt Issuance Costs | 200 | ||||||
Loss on early extinguishment of debt | $ (3,300) | ||||||
Interest expense | 700 | ||||||
Term Loan [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Issuance Costs at closing | 2,900 | 2,900 | |||||
Outstanding principal, interest and final payment amount | 32,900 | ||||||
Interest expense | 1,900 | $ 1,400 | 3,800 | $ 1,600 | |||
Face value of term loan | $ 50,000 | ||||||
Fair value of term loan | 400 | 400 | |||||
Final payment | 53,900 | 53,900 | 51,900 | ||||
Fair value of derivative liability | $ 0 | $ 0 | $ 600 | ||||
Term Loan [Member] | Senior Credit Agreement | |||||||
Debt Instrument [Line Items] | |||||||
Outstanding principal, interest and final payment amount | $ 30,000 | ||||||
Term A Loan [Member] | Warrant [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Common Stock Issued As Warrant Exercisable | 71,522 | 71,522 | |||||
Warrant Exercise Price Per Share | $ 8.39 | $ 8.39 | |||||
Term B Loan [Member] | Warrant [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Common Stock Issued As Warrant Exercisable | 23,166 | 23,166 | |||||
Warrant Exercise Price Per Share | $ 12.95 | $ 12.95 |
Common Stock - Additional Infor
Common Stock - Additional Information (Details) - USD ($) | 1 Months Ended | 6 Months Ended | |
May 31, 2022 | Jun. 30, 2023 | Dec. 31, 2022 | |
Common Stock, Shares, Issued | 23,749,005 | 23,739,313 | |
2022 ATM Program | |||
Common Stock, Shares, Issued | 45,000,000 | ||
Common Stock [Member] | |||
Common stock, voting rights | Each share of common stock has the right to one vote. | ||
Cash dividends declared | $ 0 | ||
Common Stock [Member] | 2022 ATM Program | |||
Gross Sales proceeds from Common stock issuance | $ 50,000,000 |
Common Stock - Schedule of Rese
Common Stock - Schedule of Reserved Shares of Common Stock for Issuance, on an as-Converted Basis (Details) - shares | Jun. 30, 2023 | Dec. 31, 2022 |
Stock Incentive Plans [Member] | ||
Issuance of common stock, net of issuance costs | 7,776,500 | 6,351,263 |
Common Stock Warrants [Member] | ||
Issuance of common stock, net of issuance costs | 94,688 | 94,688 |
Redeemable Convertible Preferred Stock Warrant [Member] | ||
Issuance of common stock, net of issuance costs | 7,871,188 | 6,445,951 |
Stock Incentive Plan - Addition
Stock Incentive Plan - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Long-Term Debt, Description | The term loans accrued interest at the greater of (i) 7.95% or (ii) the sum of (a) the greater of (1) the thirty (30) day U.S. LIBOR or (2) 0.11%, plus (b) 7.84% | ||||||
Number of Options, Beginning Balance | 4,629,027 | 4,629,027 | 4,275,909 | ||||
Remaining Contractual Term (Years), Exercisable | 6 years 3 months 18 days | ||||||
Number of shares available for grant | 2,894,973 | 2,894,973 | 1,837,854 | ||||
Stock options, grants in period | 1,145,643 | ||||||
Stock options, grants in period, weighted-average exercise price | $ 2.23 | ||||||
Unvested stock options, cost not yet recognized, amount | $ 8.9 | $ 8.9 | |||||
Unvested award, cost not yet recognized, period for recognition | 2 years 4 months 24 days | ||||||
Stock Options [Member] | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Award expiration period | 10 years | ||||||
Remaining Contractual Term (Years), Exercisable | 4 years | ||||||
Expected dividend yield | 0% | 0% | 0% | 0% | |||
PSUs [Member] | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Unvested stock options, cost not yet recognized, amount | $ 0.1 | $ 0.1 | |||||
Unvested award, cost not yet recognized, period for recognition | 10 months 24 days | ||||||
Number of Shares, Vested | 0 | ||||||
Outstanding shares | 205,000 | 205,000 | 237,500 | ||||
Expected dividend yield | 0% | 0% | |||||
2021 Stock Incentive Plan [Member] | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Increase in number of shares available for future grant | 1,186,965 | ||||||
Percentage of total number of outstanding shares of common stock | 5% | ||||||
2021 Equity Incentive Plan Policies [Member] | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Number of Options, Beginning Balance | 4,881,927 | 4,881,927 | |||||
Issuance of common stock, net of issuance costs | 7,776,500 | 7,776,500 | |||||
Number of shares available for grant | 2,894,973 | 2,894,973 | |||||
2021 Employee Stock Purchase Plan [Member] | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Increase in number of shares available for future grant | 237,393 | ||||||
Percentage of total number of outstanding shares of common stock | 5% | ||||||
Total Shareholder Return (TSR) [Member] | PSUs [Member] | Maximum [Member] | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Target Shares Granted | 150% | 125% | |||||
Total Shareholder Return (TSR) [Member] | PSUs [Member] | Minimum [Member] | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Target Shares Granted | 0% | 0% |
Stock Incentive Plans - Changes
Stock Incentive Plans - Changes In Shares Available For Grant Under The 2021 Plan (Details) | 6 Months Ended |
Jun. 30, 2023 shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Shares Available for Grant, Beginning Balance | 1,837,854 |
Options and restricted units granted | (1,193,143) |
Options and restricted units forfeited, cancelled, or expired | 825,904 |
Shares Available for Grant, Ending Balance | 2,894,973 |
2021 Stock Incentive Plan [Member] | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Increase in number of shares available for future grant | 1,186,965 |
2021 Employee Stock Purchase Plan [Member] | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Increase in number of shares available for future grant | 237,393 |
Stock Incentive Plan - Schedule
Stock Incentive Plan - Schedule of Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation expense | $ 1,099 | $ 1,579 | $ 2,418 | $ 3,374 |
Cost of goods sold [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation expense | 59 | 23 | 76 | 54 |
Research and Development [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation expense | 54 | 199 | 224 | 610 |
Selling, general and administrative [Member] | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation expense | $ 986 | $ 1,357 | $ 2,118 | $ 2,710 |
Stock Incentive Plan - Summary
Stock Incentive Plan - Summary of the Company's Stock Option Activity under its Stock Option Plans (Details) $ / shares in Units, $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2023 USD ($) $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | |
Share-Based Payment Arrangement [Abstract] | ||
Number of Options, Beginning Balance | shares | 4,275,909 | |
Number of Options, Granted | shares | 1,145,643 | |
Number of options, exercised | shares | (2,748) | |
Number of Options, Cancelled | shares | (789,777) | |
Number of Options, Ending Balance | shares | 4,629,027 | 4,275,909 |
Number of Options, Exercisable | shares | 2,491,654 | |
Weighted-Average Exercise Price, Beginning Balance | $ / shares | $ 8.08 | |
Weighted-Average Exercise Price, Granted | $ / shares | 2.23 | |
Weighted-Average Exercise Price, Exercised | $ / shares | 1.97 | |
Weighted-Average Exercise Price, Cancelled | $ / shares | 5.45 | |
Weighted-Average Exercise Price, Ending Balance | $ / shares | 6.82 | $ 8.08 |
Weighted-Average Exercise Price, Exercisable | $ / shares | $ 7.10 | |
Remaining Contractual Term (Years), Balance | 7 years 6 months | 7 years 6 months |
Remaining Contractual Term (Years), Exercisable | 6 years 3 months 18 days | |
Aggregate Intrinsic Value, Beginning Balance | $ | $ 1,038 | |
Aggregate Intrinsic Value, Ending Balance | $ | 0 | $ 1,038 |
Aggregate Intrinsic Value, Exercisable | $ | $ 0 |
Stock Incentive Plan - Schedu_2
Stock Incentive Plan - Schedule of Fair Value of Stock Option Awards Granted to Employees (Details) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2021 | |
Stock Options [Member] | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Expected term (in years) | 6 years 1 month 6 days | 6 years 1 month 6 days | 6 years 1 month 6 days | 6 years 1 month 6 days | |
Expected dividends | 0% | 0% | 0% | 0% | |
Stock Options [Member] | Minimum [Member] | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Expected volatility | 71.30% | 72.70% | 70.70% | 72.70% | |
Risk-free interest rate | 3.38% | 2.79% | 3.38% | 1.70% | |
Stock Options [Member] | Maximum [Member] | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Expected volatility | 71.40% | 73.40% | 71.40% | 73.40% | |
Risk-free interest rate | 3.94% | 3.33% | 3.95% | 3.33% | |
PSUs [Member] | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Expected term (in years) | 2 years 1 month 6 days | ||||
Expected volatility | 0.83% | ||||
Risk-free interest rate | 0.70% | ||||
Expected dividends | 0% | 0% |
Stock Incentive Plan - Summar_2
Stock Incentive Plan - Summary of Restricted Stock Unit Activity (Details) | 6 Months Ended |
Jun. 30, 2023 shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Number of Options, Granted | 1,145,643 |
PSUs [Member] | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Number of shares Unvested, Beginning Balance | 237,500 |
Number of Shares, Vested | 0 |
Number of shares Unvested, Ending Balance | 205,000 |
Defined Contribution Plan - Add
Defined Contribution Plan - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Retirement Benefits [Abstract] | ||||
Maximum Employee's Contribution, Percent | 4% | |||
Expense, Defined Contribution Plan | $ 0.2 | $ 0.2 | $ 0.5 | $ 0.4 |
Net Loss Per Share - Schedule o
Net Loss Per Share - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount | 4,976,215 | 4,716,160 |
Stock Options [Member] | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount | 4,629,027 | 4,135,901 |
Non-vested PSUs [Member] | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount | 252,500 | 485,571 |
Stock Warrants [Member] | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount | 94,688 | 94,688 |